Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma

Niedzwiecki, Donna; Hollis, Donna; Schilsky, Richard L.; Mayer, Robert J.

doi:10.1002/1097-0142(20010401)91:7<1256::aid-cncr1126>3.0.co;2-v

Cited by 15 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, attempts have been made to obtain superior antitumor activity in 5-U based chemotherapy by inhibiting DPD activity. Several oral fluoropyrimidine derivatives combined with DPD inhibitory agents have been developed [40][41][42][43]. UFT is a combination drug consisting of 1M tegafur and 4 M uracil.…”

Section: Discussionmentioning

confidence: 99%

Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer

et al. 2003

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer

et al. 2003

View full text Add to dashboard Cite

“…Other chemotherapeutic agents are now being studied such as oral fluoropyrimidines (UTF, capecitabine), and raltitrexed (Tomudex), and they demonstrate equivalence in response rates with better tolerance when compared to classic regimens, with the advantage of oral administration in many cases. However, improvement in survival has not been achieved (33)(34)(35). The main multicenter randomized phase III studies of adjuvant chemotherapy are shown in table II.…”

Section: Adjuvants With Systemic Chemotherapy In Advanced Cancer Of Tmentioning

confidence: 99%

Peritoneal carcinomatosis of colorectal origin. Current treatment: Review and update

Portilla¹,

Cendoya

Tejada

et al. 2005

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

Colorectal cancer is the most frequent tumor of the digestive tract. The high incidence of abdominal dissemination; the poor prognosis of these patients, with median survival consistently ranging from 5 to 9 months in all studies of peritoneal carcinomatosis from colorectal cancer; the failure of adjuvant systemic chemotherapy treatment with a maximal survival of 18 months despite the development of new cytostatic drugs, and new combinations of use, make it crucial to search for and develop new treatment strategies. We review the principles of Sugarbaker´s treatment protocol, which involves the combination of maximum cytoreductive radical oncological surgery for the treatment of all macroscopically disseminated disease with maximum perioperative intraperitoneal intensification chemotherapy to treat residual microscopic disease. We present the results of several scientific papers, all of them phase II studies with more than 10 patients treated, published in the medical literature by the main groups working in this line of treatment, together with the only phase III study reported and published so far, and finally the results of a recently reported retrospective international multicenter study. With this new alternative therapeutic approach, overall mean survival is 40% at 36 months, and 20% at 5 years. Based on these results, this new therapeutic approach is proposed as the treatment of choice for these unfortunate patients.

show abstract

“…It is a pyrimidine analog that restrains the biosynthesis of deoxyribonucleotides for DNA replication through constraining thymidylate synthase activity, resulting to thymidine exhaustion, incorporation of deoxyuridine triphosphate into DNA and subsequently causing cell death [ 39 – 41 ]. However, 5-FU has limitations, such as short biological half-life due to rapid metabolism, non-uniform and incomplete oral absorption owing to metabolism by dihydropyrimidine dehydrogenase [ 42 – 45 ], toxic side effects on bone marrow and gastrointestinal tract, and non-selective action against healthy cells [ 46 ]. For successful cancer treatment, overcoming the toxic side effects on bone marrow is highly essential, which might possibly be achieved by the control release of the drug by intercalated in the clay interlayer and biopolymeric systems.…”

Section: Introductionmentioning

confidence: 99%

5-Fluorouracil Loaded Chitosan–PVA/Na+MMT Nanocomposite Films for Drug Release and Antimicrobial Activity

et al. 2016

View full text Add to dashboard Cite

In the present study, chitosan and polyvinyl alcohol (PVA) were blended with different concentrations of sodium montmorillonite (Na+MMT) clay solution by a solvent casting method. X-ray diffraction and transition electron microscope results show that the film properties are related to the co-existence of Na+MMT intercalation/exfoliation in the blend and the interaction between chitosan–PVA and Na+MMT. 5-Fluorouracil (5-FU) was loaded with chitosan–PVA/Na+MMT nanocomposite films for in vitro drug delivery study. The antimicrobial activity of the chitosan–PVA/Na+MMT films showed significant effect against Salmonella (Gram-negative) and Staphylococcus aureus (Gram-positive), whereas 5-FU encapsulated chitosan–PVA/Na+MMT bio-nanocomposite films did not show any inhibition against bacteria. Our results indicate that combination of a flexible and soft polymeric material with high drug loading ability of a hard inorganic porous material can produce improved control over degradation and drug release. It will be an economically viable method for preparation of advanced drug delivery vehicles and biodegradable implants or scaffolds.

show abstract

Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma

Cited by 15 publications

References 13 publications

Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer

Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer

Peritoneal carcinomatosis of colorectal origin. Current treatment: Review and update

5-Fluorouracil Loaded Chitosan–PVA/Na+MMT Nanocomposite Films for Drug Release and Antimicrobial Activity

Contact Info

Product

Resources

About